Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Should All Donors Be Treated by Ex Vivo Lung Perfusion?-Reply.

Tikkanen JM, Divithotawela C, Cypel M.

JAMA Surg. 2020 Mar 25. doi: 10.1001/jamasurg.2020.0049. [Epub ahead of print] No abstract available.

PMID:
32211846
2.

Extending cytomegalovirus prophylaxis in high-risk (D+/R-) lung transplant recipients from 6 to 9 months reduces cytomegalovirus disease: A retrospective study.

Herrera S, Khan B, Singer LG, Binnie M, Chaparro C, Chow CW, Martinu T, Tomlinson G, Keshavjee S, Husain S, Tikkanen JM.

Transpl Infect Dis. 2020 Mar 14:e13277. doi: 10.1111/tid.13277. [Epub ahead of print]

PMID:
32170813
3.

Intragraft donor-specific antibodies and lung transplantation.

Tikkanen JM, Tinckam K.

Eur Respir J. 2019 Nov 7;54(5). pii: 1901937. doi: 10.1183/13993003.01937-2019. Print 2019 Nov. No abstract available.

PMID:
31699784
4.

Long-term Outcomes of Lung Transplant With Ex Vivo Lung Perfusion.

Divithotawela C, Cypel M, Martinu T, Singer LG, Binnie M, Chow CW, Chaparro C, Waddell TK, de Perrot M, Pierre A, Yasufuku K, Yeung JC, Donahoe L, Keshavjee S, Tikkanen JM.

JAMA Surg. 2019 Oct 9. doi: 10.1001/jamasurg.2019.4079. [Epub ahead of print]

PMID:
31596484
5.

Epithelial cell death markers in bronchoalveolar lavage correlate with chronic lung allograft dysfunction subtypes and survival in lung transplant recipients-a single-center retrospective cohort study.

Levy L, Tigert A, Huszti E, Saito T, Mitsakakis N, Moshkelgosha S, Joe B, Boonstra KM, Tikkanen JM, Keshavjee S, Juvet SC, Martinu T.

Transpl Int. 2019 Sep;32(9):965-973. doi: 10.1111/tri.13444. Epub 2019 May 15.

PMID:
31002407
6.

Identification of risk epitope mismatches associated with de novo donor-specific HLA antibody development in cardiothoracic transplantation.

McCaughan JA, Battle RK, Singh SKS, Tikkanen JM, Moayedi Y, Ross HJ, Singer LG, Keshavjee S, Tinckam KJ.

Am J Transplant. 2018 Dec;18(12):2924-2933. doi: 10.1111/ajt.14951. Epub 2018 Jun 22.

7.

De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation.

Tikkanen JM, Singer LG, Kim SJ, Li Y, Binnie M, Chaparro C, Chow CW, Martinu T, Azad S, Keshavjee S, Tinckam K.

Am J Respir Crit Care Med. 2016 Sep 1;194(5):596-606. doi: 10.1164/rccm.201509-1857OC.

PMID:
26967790
8.

Increased myeloid cell hypoxia-inducible factor-1 delays obliterative airway disease in the mouse.

Ropponen JO, Keränen MA, Raissadati A, Nykänen AI, Krebs R, Lemström KB, Tikkanen JM.

J Heart Lung Transplant. 2016 May;35(5):671-8. doi: 10.1016/j.healun.2015.12.021. Epub 2016 Jan 6.

PMID:
26856676
9.

Functional outcomes and quality of life after normothermic ex vivo lung perfusion lung transplantation.

Tikkanen JM, Cypel M, Machuca TN, Azad S, Binnie M, Chow CW, Chaparro C, Hutcheon M, Yasufuku K, de Perrot M, Pierre AF, Waddell TK, Keshavjee S, Singer LG.

J Heart Lung Transplant. 2015 Apr;34(4):547-56. doi: 10.1016/j.healun.2014.09.044. Epub 2014 Oct 24.

PMID:
25476845
10.

Bone morphogenetic protein-inducer tilorone identified by high-throughput screening is antifibrotic in vivo.

Leppäranta O, Tikkanen JM, Bespalov MM, Koli K, Myllärniemi M.

Am J Respir Cell Mol Biol. 2013 Apr;48(4):448-55. doi: 10.1165/rcmb.2012-0201OC.

PMID:
23258233
11.

Critical role of VEGF-C/VEGFR-3 signaling in innate and adaptive immune responses in experimental obliterative bronchiolitis.

Krebs R, Tikkanen JM, Ropponen JO, Jeltsch M, Jokinen JJ, Ylä-Herttuala S, Nykänen AI, Lemström KB.

Am J Pathol. 2012 Nov;181(5):1607-20. doi: 10.1016/j.ajpath.2012.07.021. Epub 2012 Sep 7.

PMID:
22959907
12.

Effect of simvastatin on development of obliterative airway disease: an experimental study.

Ropponen JO, Syrjälä SO, Hollmén M, Tuuminen R, Krebs R, Keränen MA, Vaali K, Nykänen AI, Lemström KB, Tikkanen JM.

J Heart Lung Transplant. 2012 Feb;31(2):194-203. doi: 10.1016/j.healun.2011.11.008.

PMID:
22305382
13.

Donor simvastatin treatment abolishes rat cardiac allograft ischemia/reperfusion injury and chronic rejection through microvascular protection.

Tuuminen R, Syrjälä S, Krebs R, Keränen MA, Koli K, Abo-Ramadan U, Neuvonen PJ, Tikkanen JM, Nykänen AI, Lemström KB.

Circulation. 2011 Sep 6;124(10):1138-50. doi: 10.1161/CIRCULATIONAHA.110.005249. Epub 2011 Aug 15.

PMID:
21844074
14.

Innate and adaptive immune responses in obliterative airway disease in rat tracheal allografts.

Ropponen JO, Syrjälä SO, Krebs R, Nykänen A, Tikkanen JM, Lemström KB.

J Heart Lung Transplant. 2011 Jun;30(6):707-16. doi: 10.1016/j.healun.2010.12.011. Epub 2011 Mar 16.

PMID:
21411341
15.

Tacrolimus treatment effectively inhibits progression of obliterative airway disease even at later stages of disease development.

Hollmén M, Tikkanen JM, Nykänen AI, Koskinen PK, Lemström KB.

J Heart Lung Transplant. 2008 Aug;27(8):856-64. doi: 10.1016/j.healun.2008.05.018. Epub 2008 Jul 3.

PMID:
18656798
16.

VEGFR-1 and -2 regulate inflammation, myocardial angiogenesis, and arteriosclerosis in chronically rejecting cardiac allografts.

Raisky O, Nykänen AI, Krebs R, Hollmén M, Keränen MA, Tikkanen JM, Sihvola R, Alhonen L, Salven P, Wu Y, Hicklin DJ, Alitalo K, Koskinen PK, Lemström KB.

Arterioscler Thromb Vasc Biol. 2007 Apr;27(4):819-25. Epub 2007 Feb 8.

PMID:
17290032
17.

Vascular endothelial growth factor plays a major role in development of experimental obliterative bronchiolitis.

Krebs R, Hollmén ME, Tikkanen JM, Wu Y, Hicklin DJ, Koskinen PK, Lemström KB.

Transplant Proc. 2006 Dec;38(10):3266-7.

PMID:
17175244
18.

Role of platelet-derived growth factor and vascular endothelial growth factor in obliterative airway disease.

Tikkanen JM, Hollmén M, Nykänen AI, Wood J, Koskinen PK, Lemström KB.

Am J Respir Crit Care Med. 2006 Nov 15;174(10):1145-52. Epub 2006 Aug 17.

PMID:
16917119
19.

Angiogenic growth factors in cardiac allograft rejection.

Nykänen AI, Tikkanen JM, Krebs R, Keränen MA, Sihvola RK, Sandelin H, Tuuminen R, Raisky O, Koskinen PK, Lemström KB.

Transplantation. 2006 Jul 15;82(1 Suppl):S22-4. Review. Erratum in: Transplantation. 2006 Sep 15;82(5):721.

PMID:
16829789
20.

Inhibition of tumor necrosis factor-alpha attenuates myocardial remodeling in rat cardiac allografts.

Sihvola RK, Koskinen PK, Pulkkinen VP, Tikkanen JM, Lemström KB.

J Heart Lung Transplant. 2006 May;25(5):569-78. Epub 2006 Apr 11.

PMID:
16678037
21.

Dual role of vascular endothelial growth factor in experimental obliterative bronchiolitis.

Krebs R, Tikkanen JM, Nykänen AI, Wood J, Jeltsch M, Ylä-Herttuala S, Koskinen PK, Lemström KB.

Am J Respir Crit Care Med. 2005 Jun 15;171(12):1421-9. Epub 2005 Mar 18.

PMID:
15778488
22.

Combined vascular endothelial growth factor and platelet-derived growth factor inhibition in rat cardiac allografts: beneficial effects on inflammation and smooth muscle cell proliferation.

Nykänen AI, Krebs R, Tikkanen JM, Raisky O, Sihvola R, Wood J, Koskinen PK, Lemström KB.

Transplantation. 2005 Jan 27;79(2):182-9.

PMID:
15665766
23.

Role of angiogenic growth factors in transplant coronary artery disease.

Lemström KB, Nykänen AI, Tikkanen JM, Krebs R, Sihvola RK, Kallio EA, Olivier R, Koskinen PK.

Ann Med. 2004;36(3):184-93. Review.

PMID:
15181974
24.

Role of endogenous endothelin-1 in transplant obliterative airway disease in the rat.

Tikkanen JM, Koskinen PK, Lemström KB.

Am J Transplant. 2004 May;4(5):713-20.

25.

Platelet-derived growth factor regulates cytomegalovirus infection-enhanced obliterative bronchiolitis in rat tracheal allografts.

Tikkanen JM, Krebs R, Bruggeman C, Lemström KB, Koskinen PK.

Transplantation. 2004 Mar 15;77(5):655-8.

PMID:
15021824
26.

Platelet-derived growth factor receptor inhibition reduces allograft arteriosclerosis of heart and aorta in cholesterol-fed rabbits.

Sihvola RK, Tikkanen JM, Krebs R, Aaltola EM, Buchdunger E, Laitinen O, Koskinen PK, Lemström KB.

Transplantation. 2003 Feb 15;75(3):334-9.

PMID:
12589154
27.

Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis.

Lemström KB, Krebs R, Nykänen AI, Tikkanen JM, Sihvola RK, Aaltola EM, Häyry PJ, Wood J, Alitalo K, Ylä-Herttuala S, Koskinen PK.

Circulation. 2002 May 28;105(21):2524-30.

PMID:
12034660
28.
29.

Prevention of cytomegalovirus infection-enhanced experimental obliterative bronchiolitis by antiviral prophylaxis or immunosuppression in rat tracheal allografts.

Tikkanen JM, Kallio EA, Bruggeman CA, Koskinen PK, Lemström KB.

Am J Respir Crit Care Med. 2001 Aug 15;164(4):672-9.

PMID:
11520736
30.

Cytomegalovirus infection and cardiac allograft vasculopathy.

Koskinen PK, Kallio EA, Tikkanen JM, Sihvola RK, Häyry PJ, Lemström KB.

Transpl Infect Dis. 1999 Jun;1(2):115-26. Review.

PMID:
11428979
31.

Obliterative bronchiolitis: prevention.

Kallio EA, Koskinen PK, Tikkanen JM, Lemström KB.

Transplant Proc. 2001 Feb-Mar;33(1-2):1617-9. No abstract available.

PMID:
11267443
32.

CD28-B7-2 but not CD28-B7-1 interaction is required for T cell costimulation in experimental obliterative bronchiolitis in the rat.

Tikkanen JM, Lemström KB, Koskinen PK.

Transplant Proc. 2001 Feb-Mar;33(1-2):535. No abstract available.

PMID:
11266944
33.

Endothelin-1 is biologically active in experimental rat obliterative bronchiolitis.

Pulkkinen VP, Tikkanen JM, Lemström KB, Koskinen PK.

Transplant Proc. 2001 Feb-Mar;33(1-2):406. No abstract available.

PMID:
11266885
34.

CD28/B7-2 pathway regulates the development of experimental obliterative bronchiolitis via promotion of TH1 cytokine expression.

Tikkanen JM, Lemstrom K, Pulkkinen VP, Koskinen PK.

J Heart Lung Transplant. 2001 Feb;20(2):252-253. No abstract available.

PMID:
11250501
35.

Blockade of PDGF receptor protein-tyrosine kinase activity effectively inhibits development of rat CMV infection enhanced experimental obliterative bronchiolitis.

Tikkanen JM, Lemstrom K, Koskinen PK.

J Heart Lung Transplant. 2001 Feb;20(2):167. No abstract available.

PMID:
11250257
37.

Exploring the substrate specificities of alpha-2,6- and alpha-2,3-sialyltransferases using synthetic acceptor analogues.

Van Dorst JA, Tikkanen JM, Krezdorn CH, Streiff MB, Berger EG, Van Kuik JA, Kamerling JP, Vliegenthart JF.

Eur J Biochem. 1996 Dec 15;242(3):674-81.

Supplemental Content

Loading ...
Support Center